» Articles » PMID: 22194931

Assessing Recent Smoking Status by Measuring Exhaled Carbon Monoxide Levels

Overview
Journal PLoS One
Date 2011 Dec 24
PMID 22194931
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cigarette smoke causes both acute and chronic changes of the immune system. Excluding recent smoking is therefore important in clinical studies with chronic inflammation as primary focus. In this context, it is common to ask the study subjects to refrain from smoking within a certain time frame prior to sampling. The duration of the smoking cessation is typically from midnight the evening before, i.e. 8 hours from sampling. As it has been shown that a proportion of current smokers underestimates or denies smoking, objective assessment of recent smoking status is of great importance. Our aim was to extend the use of exhaled carbon monoxide (CO(breath)), a well-established method for separating smokers from non-smokers, to assessment of recent smoking status.

Methods And Findings: The time course of CO(breath) decline was investigated by hourly measurements during one day on non-symptomatic smokers and non-smokers (6+7), as well as by measurements on three separate occasions on non-smokers (n = 29), smokers with normal lung function (n = 38) and smokers with chronic obstructive pulmonary disease (n = 19) participating in a clinical study. We used regression analysis to model the decay, and receiver operator characteristics analysis for evaluation of model performance. The decline was described as a mono-exponential decay (r(2) = 0.7) with a half-life of 4.5 hours. CO decline rate depends on initial CO levels, and by necessity a generic cut-off is therefore crude as initial CO(breath) varies a lot between individuals. However, a cut-off level of 12 ppm could classify recent smokers from smokers having refrained from smoking during the past 8 hours with a specificity of 94% and a sensitivity of 90%.

Conclusions: We hereby describe a method for classifying recent smokers from smokers having refrained from smoking for >8 hours that is easy to implement in a clinical setting.

Citing Articles

Integrated Nicotine Replacement and Behavioral Support to Reduce Smoking in Opioid Agonist Therapy: A Randomized Clinical Trial.

Druckrey-Fiskaaen K, Madebo T, Daltveit J, Vold J, Furulund E, Chalabianloo F JAMA Psychiatry. 2025; .

PMID: 39937506 PMC: 11822603. DOI: 10.1001/jamapsychiatry.2024.4801.


An mHealth Intervention With Financial Incentives to Promote Smoking Cessation and Physical Activity Among Black Adults: Protocol for a Feasibility Randomized Controlled Trial.

Alexander A, Businelle M, Cheney M, Cohn A, McNeill L, Short K JMIR Res Protoc. 2025; 14:e69771.

PMID: 39888657 PMC: 11829183. DOI: 10.2196/69771.


Expression Levels of MUC5AC and MUC5B in Airway Goblet Cells Are Associated with Traits of COPD and Progression of Chronic Airflow Limitation.

Pincikova T, Merikallio H, Kotortsi I, Karimi R, Li C, Lappi-Blanco E Int J Mol Sci. 2025; 25(24.

PMID: 39769414 PMC: 11678853. DOI: 10.3390/ijms252413653.


The challenges of recruiting never-smokers with chronic obstructive pulmonary disease from the large population-based Swedish CArdiopulmonary bioImage study (SCAPIS) cohort.

Sonnerfors P, Jacobson P, Andersson A, Behndig A, Bjermer L, Blomberg A Eur Clin Respir J. 2024; 11(1):2372903.

PMID: 39015382 PMC: 11251440. DOI: 10.1080/20018525.2024.2372903.


Financial incentive interventions for smoking cessation among Chinese smokers: study protocol for a cluster randomised controlled trial.

Yang X, Galarraga O, Cao W, Lin H, Cao F, Chang C BMJ Open. 2024; 14(4):e080344.

PMID: 38684254 PMC: 11086505. DOI: 10.1136/bmjopen-2023-080344.


References
1.
Pauwels R, Buist A, Calverley P, Jenkins C, Hurd S . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001; 163(5):1256-76. DOI: 10.1164/ajrccm.163.5.2101039. View

2.
Kharitonov S, Barnes P . Exhaled markers of pulmonary disease. Am J Respir Crit Care Med. 2001; 163(7):1693-722. DOI: 10.1164/ajrccm.163.7.2009041. View

3.
Bakhru A, Erlinger T . Smoking cessation and cardiovascular disease risk factors: results from the Third National Health and Nutrition Examination Survey. PLoS Med. 2005; 2(6):e160. PMC: 1160573. DOI: 10.1371/journal.pmed.0020160. View

4.
Liu J, Liang Q, Frost-Pineda K, Muhammad-Kah R, Rimmer L, Roethig H . Relationship between biomarkers of cigarette smoke exposure and biomarkers of inflammation, oxidative stress, and platelet activation in adult cigarette smokers. Cancer Epidemiol Biomarkers Prev. 2011; 20(8):1760-9. DOI: 10.1158/1055-9965.EPI-10-0987. View

5.
Sato S, Nishimura K, Koyama H, Tsukino M, Oga T, Hajiro T . Optimal cutoff level of breath carbon monoxide for assessing smoking status in patients with asthma and COPD. Chest. 2003; 124(5):1749-54. DOI: 10.1378/chest.124.5.1749. View